CCL2 and chronic kidney disease: A prospective study 33 enrolled 215 patients with CKD, among whom 43 patients presented IgAN, to assess the relationships between ACR levels, urinary monocyte chemoattractant protein-1 (MCP-1) levels, macrophage numbers, in situ damage and clinical outcomes.